CPTAC

CPTAC
Name	Clinical Proteomic Tumor Analysis Consortium
Established	2011
Headquarters	United States
Parent organization	National Cancer Institute
Focus	Proteomics, Cancer Biology, Biomarkers
Website	N/A

CPTAC

The Clinical Proteomic Tumor Analysis Consortium is a United States-based research consortium focused on large-scale proteomic characterization of human tumors to advance translational oncology. It brings together investigators from academic centers, national laboratories, biotechnology companies, and funding agencies to integrate proteomics with genomics and clinical data for improved biomarker discovery, therapeutic target identification, and molecular classification. The consortium emphasizes standardized workflows, reproducible data, and public resource generation to support precision oncology and systems biology.

Overview

The consortium conducts comprehensive proteomic profiling of tumor specimens from major initiatives such as The Cancer Genome Atlas and collaborates with programs like International Cancer Genome Consortium, Human Proteome Project, ProteomeXchange Consortium, Genomic Data Commons, and NIH Common Fund initiatives. Its activities intersect with institutions including National Cancer Institute, Broad Institute, Lawrence Berkeley National Laboratory, Pacific Northwest National Laboratory, and Fédération Française de la Recherche sur le Cancer. The consortium’s outputs include mass spectrometry datasets, assay libraries, informatics tools, and benchmarked protocols used by researchers at Dana-Farber Cancer Institute, Johns Hopkins University, Memorial Sloan Kettering Cancer Center, and University of California, San Diego.

History and Development

Initiated in the early 2010s under programs administered by the National Institutes of Health and the National Cancer Institute, the consortium was formed to fill gaps between genomic catalogs from projects like The Cancer Genome Atlas and the functional protein-level events that drive oncogenesis. Early pilot phases involved collaborations with Proteomics Standards Initiative, Human Proteome Organization, and federal laboratories such as Argonne National Laboratory and Oak Ridge National Laboratory. Subsequent funding rounds expanded participation to groups at University of Texas MD Anderson Cancer Center, Yale University, Washington University in St. Louis, and industry partners including Thermo Fisher Scientific and Agilent Technologies to scale mass spectrometry capacity and assay development.

Organization and Governance

The consortium’s governance model includes steering committees, working groups, and data access committees drawn from awardee institutions, federal program officers, and external advisors. Leadership roles have been held by investigators affiliated with University of Colorado, University of Pennsylvania, Massachusetts General Hospital, and University of Michigan. Operational oversight interacts with compliance offices at National Institutes of Health and policy frameworks such as those used by ClinicalTrials.gov and the Office of Research Integrity. Working groups focus on domains like sample handling, assay standardization, informatics, and clinical annotation, coordinating with standards bodies including International Organization for Standardization where relevant.

Research Programs and Methodologies

Research programs cover tumor types represented in consortia like The Cancer Genome Atlas—including breast cancer, colorectal cancer, lung adenocarcinoma, ovarian carcinoma, and glioblastoma multiforme—and employ techniques developed in collaboration with centers such as Scripps Research Institute and Cold Spring Harbor Laboratory. Methodologies emphasize quantitative mass spectrometry approaches—such as data-dependent acquisition, data-independent acquisition, and targeted selected reaction monitoring—implemented on platforms by Thermo Fisher Scientific and Sciex. The consortium integrates proteogenomic pipelines merging datasets from Illumina sequencing efforts, peptide spectral libraries, and open-source tools like MaxQuant, Perseus, and OpenMS to map proteins to genomic alterations from projects including 1000 Genomes Project and Exome Aggregation Consortium.

Key Findings and Impact

Consortium analyses have revealed post-translational modifications, signaling network rewiring, and proteoform diversity that refine molecular subtypes initially defined by genomic studies such as The Cancer Genome Atlas. High-impact discoveries include identification of phosphoproteomic signatures associated with therapeutic response in HER2-positive breast cancer, proteomic stratification of clear cell renal cell carcinoma, and insights into metabolic reprogramming in glioblastoma multiforme. These results have influenced biomarker efforts at Food and Drug Administration-regulated clinical assay development and have been cited in translational programs at National Comprehensive Cancer Network institutions. The consortium’s standardized assays and best-practice protocols have been adopted by clinical proteomics initiatives in Europe and Asia, complementing efforts led by European Molecular Biology Laboratory and Riken.

Collaborations and Partnerships

CPTAC partners include federal agencies, academic hubs, private-sector instrument vendors, and international research initiatives. Notable collaborators encompass National Cancer Institute, Broad Institute, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Thermo Fisher Scientific, Sciex, Agilent Technologies, and consortia like International Cancer Genome Consortium and Human Proteome Project. These partnerships support shared resources, cross-validation studies, method harmonization, and training programs with organizations such as American Association for Cancer Research and Cold Spring Harbor Laboratory courses.

Data Resources and Accessibility

The consortium publishes datasets, analysis pipelines, and spectral libraries to public repositories aligned with infrastructures like ProteomeXchange Consortium, PRIDE, and the Genomic Data Commons. Data access policies balance controlled-access clinical annotations with open-access proteomic matrices to enable secondary analysis by investigators at Stanford University, University of California, San Francisco, University of Oxford, and other centers. Tools and knowledge resources are accessible through portals maintained by collaborating institutions, facilitating reuse by computational groups using platforms such as Galaxy Project and programming ecosystems like Bioconductor and Python-based frameworks.

Category:Proteomics